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Abstract
Background: c-Met signaling has been implicated in oncogenesis especially in cells with c-met gene amplification.
Since 20 % of gastric cancer patients show high level of c-Met expression, c-Met has been identified as a good
candidate for targeted therapy in gastric cancer. Herein, we report our newly synthesized c-Met inhibitor by
showing its efficacy both in vitro and in vivo.
Methods: Compounds with both triazolopyrazine and pyridoxazine scaffolds were synthesized and tested using
HTRF c-Met kinase assay. We performed cytotoxic assay, cellular phosphorylation assay, and cell cycle assay to
investigate the cellular inhibitory mechanism of our compounds. We also conducted mouse xenograft assay to
see efficacy in vivo.
Results: KRC-00509 and KRC-00715 were selected as excellent c-Met inhibitors through biochemical assay, and
exhibited to be exclusively selective to c-Met by kinase panel assay. Cytotoxic assays using 18 gastric cancer cell
lines showed our c-Met inhibitors suppressed specifically the growth of c-Met overexpressed cell lines, not that of
c-Met low expressed cell lines, by inducing G1/S arrest. In c-met amplified cell lines, c-Met inhibitors reduced the
downstream signals including Akt and Erk as well as c-Met activity. In vivo Hs746T xenograft assay showed
KRC-00715 reduced the tumor size significantly.
Conclusions: Our in vitro and in vivo data suggest KRC-00715 is a potent and highly selective c-Met inhibitor
which may have therapeutic potential in gastric tumor with c-Met overexpression.
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Background
Oncogene addiction, which was first proposed by Dr.
Bernard Weinstein, offers a rationale for the recent tar-
geted therapy in cancer biology [1]. Oncogene addiction
refers to the phenomenon which the tumorigenesis is
dependent on a specific cellular signal. In view of oncogene
addiction, RTKs have been highlighted as promising
therapeutic targets against cancer for their links with
various malignancies [2]. The clinical success of tyrosine
kinase inhibitors, such as imatinib and erlotinib, prompted
intensive studies to identify additional oncogenic proteins
for the targeted therapy. c-Met is one of the most genetic-
ally amplified and dysregulated RTKs in a subset of solid
tumor implicating it as a prominent therapeutic target.
The c-MET receptor tyrosine kinase forms a hetero-
dimer and consists of an extracellular α-chain and a
membrane-spanning β-chain [3, 4]. c-MET is the only
known high-affinity receptor for HGF [5]. Upon HGF
binding, c-Met auto-phosphorylation happens on Y1234
and Y1235 within the activation loop of kinase domain,
which promotes the kinase activity. Phosphorylated Y1349
and Y1356 serve as docking sites for the intracellular
adapters which transmit signals downstream [6, 7]. Both
c-Met and HGF are required for normal mammalian de-
velopment [8]. After birth, c-Met activation by HGF is
likely to be involved in epithelial-mesenchymal transition
* Correspondence: suchoi@krict.re.kr
1Bio-Organic Science Division, Korea Research Institute of Chemical
Technology, PO Box 107, Daejeon 305-600, Republic of Korea
Full list of author information is available at the end of the article
© 2016 Park et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Park et al. BMC Cancer  (2016) 16:35 
DOI 10.1186/s12885-016-2058-y
(EMT), as well as hepatic, renal and epidermis regener-
ation [9, 10]. c-Met overexpression by gene amplification
has been reported in a number of solid tumors, and the
resultant aberrant c-Met signaling appears to promote the
growth, maintenance, survival and progression of cancer
[11]. ShRNA-mediated c-Met knockdown induced sig-
nificant growth inhibition in c-met amplified cell lines,
whereas it had no effect on the cell lines without c-met
amplification [12]. It strongly suggests the overexpression
of c-Met by genomic amplification confers the constitutive
activity on c-Met kinase, which eventually allows the cells
to be exclusively dependent on c-Met signaling for prolif-
eration and survival [12, 13]. It has been reported that 4 %
of esophageal and 4 % of lung cancer patients have ampli-
fied c-met gene. Moreover, a large number of reports iden-
tified c-met amplification even in 10–20 % of gastric cancer
[14–18]. It means c-Met is a most relevant target for gastric
cancer therapy over other malignancies [19].
Gastric cancer is the second leading cause of cancer
related mortality worldwide with the incidence of 18.9/
100,000/year [20]. Molecules targeting EGFR, VEGF,
PI3K/Akt/mTor signal pathway, and c-Met pathway
have been investigated for molecular targeted therapy
for gastric cancer [21]. Especially, c-Met has been fairly
highlighted as a promising target in gastric cancer, for
several papers described significant growth suppression
by c-Met inhibitors [22–24].
Various approaches have been conducted to inhibit the
aberrant c-Met kinase activity, such as c-Met biologics,
HGF antagonist peptides, and HGF antibodies as well as
small molecule inhibitors [25–29]. Here, we introduce
novel potent small molecule inhibitor of c-Met and dem-
onstrate the excellence of our compounds by showing in
vitro and in vivo results.
Methods
Compounds and reagents
KRC-00509 and KRC-00715 were synthesized according
to the procedures published in patent, KR2012-0022541.
All compounds including crizotinib were dissolved in
DMSO. Compounds were formulated in 20 % PEG-400,
3 % Tween-80, 77 % distilled water for all in vivo studies.
Kinase domain of c-Met was purchased from CarnaBio
Science (JAPAN).
c-Met in vitro enzyme assay
Experiment procedure was followed by the manufactured
instruction (Cisbio, France). The reaction was initiated by
ATP addition to a mixture containing the c-Met enzyme,
peptide substrates, and inhibitors. After 30 min, EDTA
containing solution was added to stop the reaction.
EDTA containing solution has Europium conjugated
anti-phosphoresidue antibody and SA-XL665 for the
detection of the phosphorylated peptide product. After
1 h incubation, fluorescence was measured with 337 nm
excitation and dual 665 and 620 nm emission of the
Envision reader. IC50 was calculated using GraphPad
Prism version 5 for Windows. The curves were fit using
a nonlinear regression model with a log (inhibitor) versus
response formula.
Cell culture
All cell lines used in this paper, except Hs746T, were
purchased from Korean Cell Line Bank (KCLB, Korea).
Hs746T cell line was purchased from ATCC. These are
all gastric adenocarcinoma cells. SNU-5, SNU-620,
SNU-638, MKN-45, and Hs746T cell lines show high
expression of c-Met, whereas others show low level of
c-Met. These cell lines were maintained in RPMI 1640
medium supplemented with 10 % FBS (HyClone, US)
using a humidified incubator with 5 % CO2 at 37 °C.
Antibodies and immunoblotting
The following antibodies were obtained from Cell Sig-
naling Technology: c-Met (Catalog No. 3127), phospho
c-Met tyrosine 1234/1235 (Catalog No. 3129), phospho-
Erk threonine 202/204 (Catalog No. 4370), phospho-Akt
serine 473 (Catalog No. 4060), phospho-tyrosine (Catalog
No. 9416). Tubulin antibody (Catalog No. T6199) was pur-
chased from Sigma-Aldrich. HRP-conjugated anti-mouse
(Catalog No. NCI1430KR), and HRP-conjugated anti-rabbit
(Catalog No. NCI1460KR) antibodies were obtained from
Thermo Scientific. For immunoblotting, cells were washed
in PBS, lysed in 1 X sample buffer (50 mmol/L Tris–HCl
(pH 6.8), 10 % glycerol, 2 % SDS, 3 % β-mercaptoethanol),
and boiled for 10 min. Lysates were subjected to SDS-
PAGE followed by blotting with the indicated antibodies
and detection by Western blotting substrate ECL reagent
(Thermo Scientific). Images were quantified using a
LAS3000 instrument and Image Lab software.
Cell cytotoxicity assay
For viability experiments, cells were seeded in 96-well
plates at 30 % confluency and exposed to chemicals the
next day. After 72 h, WST-1 reagent was added and ab-
sorbance at 450 nm was measured on a Spectramax
spectrophotometer (Molecular Devices, US) according
to the manufacturer's instructions. IC50s were calculated
using GraphPad Prism version 5 for Windows. The
curves were fit using a nonlinear regression model with
a log (inhibitor) versus response formula.
Cell cycle analysis
We followed the manufacturer’s instruction to Nucleo-
Counter NC-250 (chemometec, Denmark) to analyze the
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cell cycle distribution. Briefly, cells treated with vehicle
or compounds for 24 h were suspended by lysis buffer
supplemented with 10ug/ml DAPI. After 5 min incubation
at 37 °C, cells were suspended by stabilization buffer. Cells
were loaded into the chambers of the slide and were ana-
lyzed by NucleoCounter NC-250.
Xenograft studies
Female athymic BALB/c (nu/nu) mice ( 6 weeks old) were
obtained from Charles River of Japan. Animals were main-
tained under clean room conditions in sterile filter top
cages and housed on high efficiency particulate air-filtered
ventilated racks. Animals received sterile rodent chow and
water ad libitum. All of the procedures were conducted in
accordance with guidelines approved by the Laboratory
Animal Care and Use Committee of Korea Research Insti-
tute of Chemical Technology. Hs746T cells (5 × 106 in
100 μl) were implanted s.c. into the right flank region of
each mouse and allowed to grow to the designated size.
Once tumors reached an average volume of 200 mm3,
mice were randomized and dosed via oral gavage daily
with the indicated doses of compounds for 10 days. Mice
were observed daily throughout the treatment period
for signs of morbidity/mortality. Tumors were measured
twice weekly using calipers, and volume was calculated
using the formula: length × width2 × 0.5. Body weight was
also assessed twice weekly. Significance differences be-
tween the treated versus the control groups (P ≤ 0.001)
were determined using one-way ANOVA.
Kinase panel assay
Kinase panel assay was done by Millipore. Kinases were
incubated with peptide together with γ-33P-ATP (specific
activity approx. 500 cpm/pmol, concentration as required).
The reaction was initiated by the addition of the MgATP
mix. After incubation for 40 min at room temperature, the
reaction was stopped by the addition of 3 % phosphoric
acid solution. 10 μl of the reaction was then spotted onto
a P30 filtermat and washed three times for 5 min in
75 mM phosphoric acid and once in methanol prior to
drying and scintillation counting.
Results
Identification of KRC-00509 and KRC-00715 as potent
inhibitors against c-Met kinase
Cui et al. suggested that PF-04217903, which has triazo-
lopyrazine scaffold, is effective for c-Met inhibition [30].
PF-04217903 binds to the hinge region through nitrogen
of quinoline in a mono binding manner. We designed
and synthesized hundreds of compounds having pyri-
doxazine instead of quinoline as a dual binder to hinge
region. The enzymatic activities were determined by HTRF
kinase assay using recombinant kinase domain of c-Met.
Among the synthesized compounds, 2 chemicals in Fig. 1
showed most potent effect against c-Met. The IC50s of
KRC-00509 and KRC-00715 were 6.3 nM and 9.0 nM, re-
spectively (Table 1, Additional file 1: Figure S1). Crizotinib,
which is under clinical trial for the c-Met over-expressed
cancer patients, [31] had IC50 value of 2.2 nM. To know
the cytotoxic activities of compounds on the c-Met-
addicted gastric cancer cells, Hs746Tcells were treated with
these inhibitors for 3 days. Hs746T cell line has constitu-
tively activated c-Met signaling by the amplified c-met gene
and a splice site mutation of exon 14 [32]. KRC-00509 and
KRC-00715 were highly cytotoxic to Hs746T cells with esti-
mated cytotoxic IC50 values of approximately 3.4 nM and
39 nM, respectively. Biochemical and cellular cytotoxic data
demonstrate that KRC-00509 and KRC-00715 are excellent
c-Met inhibitors.
KRC-00715 is highly selective to c-Met over other tyrosine
kinases
KRC-00715 was evaluated against 40 tyrosine kinases
which represent each tyrosine kinase family in enzymatic
assays by Millipore Inc. Surprisingly, as shown in Table 2,
1 μM KRC-00715 inhibited only c-Met. KRC-00715 never
Fig. 1 Chemical Structures of c-Met inhibitors
Table 1 IC50 of c-Met enzyme and cytotoxic assay
IC50 (nM) in c-Met
enzyme assay





Park et al. BMC Cancer  (2016) 16:35 Page 3 of 9
inhibited other tyrosine kinase. This data suggests that
KRC-00715 is exclusively selective to c-Met.
c-Met inhibitors selectively suppress the growth of c-Met
over-expressed gastric cancer cells
Using 18 gastric cancer cell lines, cytotoxic effects of our
c-Met inhibitors were investigated. Figure 2a shows the
c-Met expression levels in 18 gastric cancer cell lines.
SNU-5, SNU-620, SNU-638, MKN-45, and Hs746T have
high levels of total c-Met and phosphorylated c-Met
proteins, whereas other 13 gastric cancer cell lines have
extremely low levels of c-Met. 18 cancer cell lines were
treated with doxorubicin, a well-known cytotoxic drug,
for 72 h. There is no difference between c-Met over-
expressed cell lines and c-Met low-expressed cell lines in
doxorubicin-induced cytotoxic effect. In next step, these
cell lines were treated with c-Met inhibitors for 72 h.
Importantly, the cytotoxic IC50 values of c-Met inhibitors
were less than or around 10 nM in c-Met over-expressed
cell lines, whereas c-Met low-expressed cell lines were
fully viable even at 5 μM of KRC-00509 or KRC-00715
(Fig. 2). It indicates that our c-Met inhibitors don’t have
any cytotoxic effect on c-Met low-expressed gastric cancer
cells at all, but selectively suppress the growth of c-Met
over-expressed gastric cancer cells, which is consistent
with the previous reports [13]. However, unlike our c-Met
inhibitors, crizotinib, a multi-kinase inhibitor, has shown
cytotoxic effect on c-Met low-expressed cell lines to some
extent. This difference is likely because of the selectivity to
c-Met of compounds. This data strongly suggest that our
c-Met inhibitors are more relevant for the targeted therapy
for the c-Met over-expressed gastric cancer patients than
crizotinib.
c-Met inhibitors suppress c-Met auto-phosphorylation
and its downstream signals in c-Met over-expressed
gastric cancer cells
To investigate the cellular activity of inhibitors against
human c-Met kinase, the level of phospho form of c-Met at
tyrosine 1234/1235, which are auto-phosphorylation sites,
was measured in Hs746T cell line. Cells were treated with
each compound for 3 h, and lysates were prepared for west-
ern blot. As shown in Fig. 3a, c-Met auto-phosphorylations
were greatly inhibited by c-Met inhibitors. KRC-00509
showed the most excellent inhibition against c-Met auto-
phosphorylation. 8 nM KRC-00509 inhibited the c-Met
auto-phosphorylation by 70 %. Crizotinib and KRC-00715
have less activity against c-Met auto-phosphorylation than
KRC-00509. These data are consistent with the cell cyto-
toxic data (Table 1). This means that the inhibition of
c-Met activity contributes mainly to the suppression of
the Hs746T cell proliferation. To address the mechanism
by which c-Met inhibitors block the cell proliferation, we
checked the cellular phosphorylation of Erk and Akt
(Fig. 3). In cancer cells addicted to c-Met signaling, the
inhibition of c-Met activity results in the suppression of
downstream signal pathways, such as Akt and Erk, which
are important for cell survival and proliferation [6, 7]. Our
data also showed that the phosphorylations of Akt and
Erk were dramatically reduced by our c-Met inhibitors in
c-Met over-expressed gastric cancer cells such as Hs746T,
SNU-638, and SNU-620 (Fig. 3a, Additional file 1: Figure
S2A-B). However, in c-Met low-expressed cell lines, such
as AGS, SNU-1, and MKN-1, the phosphorylations of
downstream signals were not influenced by c-Met inhibi-
tors (Fig. 3b, Additional file 1: Figure S2C-D). These data
mean our c-Met inhibitors are effective only to c-Met-
Table 2 Kinase panel assay
KRC-00715 @ 1 μM KRC-00715 @ 1 μM KRC-00715 @ 1 μM
Abl 104 Fer 100 Lyn 99
Ack1 96 Fes 97 Mer 105
ALK 101 FGFR1 107 Met −2
Axl 107 Fgr 113 MuSK 106
Blk 102 Flt1 115 PDGFRα 121
Brk 96 Flt3 94 Ret 110
BTK 108 Fms 108 Ron 107
c-Ket 101 Fyn 106 Ros 115
CSK 116 Hck 81 Syk 110
DDR1 90 IGF-1R 92 Tie2 116
EGFR 111 IR 119 TrkA 99
EphA1 117 IRR 90 Yes 114
EphB1 104 JAK1 111
FAK 105 KDR 110
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addicted cells. Interestingly, Additional file 1: Figure S3
also shows that total cellular tyrosine phosphorylations in
Hs746T were diminished by c-Met inhibitors, whereas in
c-Met low expressed cell line, such as AGS, total cellular
tyrosine phosphorylations were not affected. It means
most tyrosine phosphorylations in c-Met- addicted cells
are dependent on c-Met activity, which implicates the im-
portance of c-Met in c-Met overexpressed cancer cells.
Conclusively, inhibition of c-Met activity causes the sup-
pression both of the important downstream signals and of
the total cellular tyrosine phosphorylations in c-Met over-
expressed cells leading to the cell death.
c-Met inhibitors induce G1/S arrest to suppress the cell
proliferation
To study how our c-Met inhibitors suppress the prolifer-
ation of c-Met over-expressed cells, we investigated the
cell cycle distribution (Fig. 4). SNU1 and SNU5 were
treated with our c-Met inhibitors for 24 h. SNU1 has low
expression of c-Met, whereas SNU5 has high expression
of c-Met as shown in Fig. 2. Cell cycle analysis shows cells
treated with c-Met inhibitors were arrested at G1/S phase
in SNU5. However, no cell cycle arrest was identified in
SNU1. This data implies c-Met inhibitors suppress the
cell proliferation by inducing G1/S arrest in c-Met over-
expressed cells.
KRC-00715 suppresses the tumor size in Hs746T mouse
xenograft assay
To see if our c-Met inhibitors block the tumor growth
in vivo, we used mouse Hs746T xenograft model. After
Hs746T cells were implanted on nude mouse, we ad-
ministered KRC-00509 and KRC-00715 orally at doses
of 50 mpk daily when tumor size reaches to certain point
(100 mm3 or 200 mm3). Tumor volumes were measured
about for 10 days. KRC-00715 showed very dramatic re-
sult in vivo as shown in Fig. 5a. Tumor volumes were sig-
nificantly reduced by KRC-00715. In addition, KRC-00715
administration to mouse didn’t cause any loss of weight
(Fig. 5b). However, in vivo experiment with KRC-00509
Fig. 2 c-Met inhibitors are sensitive only to c-Met over-expressed cell lines. a The lysates of 18 gastric cancer cell lines were prepared for immunoblot
with antibodies of c-Met and phospho c-Met (pY1234/1235). For cytotoxic IC50 measurement, cells were seeded on 96 well plates and were treated
with chemicals for 72 h. After 72 h, WST-1 reagent was added to each well and absorbance at 450 nm was read with microplate reader (Molecular
Device). IC50 was calculated with Prizm software program. The numbers indicate the cytotoxic micro molar IC50 (μM) of each compound.
b-c The viability curves of each gastric cancer cell line treated with KRC-00509 (b) or KRC-00715 (c)
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was suspended as mice died 3–4 days after KRC-00509
administration. Conclusively, KRC-00715 is proved to
have potent activity against c-Met in vivo as well as in
vitro.
Discussion
In this present study, we demonstrated a potent inhibi-
tor of c-Met and its excellent cytotoxic effect on c-Met
over-expressed gastric cancer cells. 10–20 % of gastric
cancer tissues and 40 % of the scirrhous histological sub-
type have been known to harbor amplified c-met gene
[14, 33, 34]. Our western blot also shows that 27 % (5/18)
of gastric cancer cell lines have c-Met overexpression
(Fig. 2a). Because cells with c-Met overexpression are
known to be addicted to c-Met signaling, the strategy
targeting c-Met may be a promising therapeutics for many
of gastric cancer patients. Previous studies demonstrated
c-Met inhibition, by siRNA or small molecule inhibitor,
blocks the proliferation of c-met amplified cancer cell
[12, 13, 35, 36]. We synthesized hundreds of compounds
and performed in vitro biochemical assay. Our compounds
have pyridoxazine instead of quinoline in PF-04217903
[30]. X-ray crystallography indicates that nitrogen of quin-
oline in PF-04217903 plays a role in hinge binding in a
mono-binding manner. Based upon our molecular docking
study, we synthesized triazolopyrazine compounds having
Fig. 3 Phosphorylations of Akt and Erk are downregulated by c-Met inhibitors only in c-Met overexpressed cell lines. Hs746T (a), or AGS (b) was
treated with c-Met inhibitors or crizotinib in a dose dependent manner for 3 h. Cell lysates were prepared for immunoblot with phospho antibodies of
c-Met, Akt, and Erk. Tubulin band shows equal loading. c-Met phosphorylation was quantified by imageJ software
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pyridoxazine as a dual-binder to hinge region. By intro-
ducing pyridoxazine, we escaped the patent conflict
with PF-04217903. KRC-00509 and KRC-00715 showed
best efficacy in enzyme assay among the synthesized ones
(Table 1, Additional file 1: Figure S1). Kinase panel assay
demonstrated KRC-00715 is exclusively selective to c-Met
like PF-04217903 (Table 2). It didn’t inhibit any tyrosine
kinase at all at 1 μM. Therefore we expect our compound
may reduce side effects to a minimal level in clinical trial.
Our cytotoxic data supports this expectation by showing
that cell lines with low level of c-Met weren’t suppressed
by our compounds at all even at as high as 5 μM (Fig. 2).
However, crizotinib, which is a multi-kinase inhibitor,
cause cytotoxic effect on several c-Met negative cell lines
to some extent. It implicates that crizotinib may cause
side effects in clinical trials, and actually several clinical
reports demonstrated it cause serious side effects includ-
ing dermatitis, visual disturbance, heart problem, and
so on [37, 38]. Table 1 indicates the cytotoxic effects of
KRC-00509 and KRC-00715 on Hs746T were as good
as crizotinib. Namely, our compounds, which inhibit c-Met
exclusively, have the same cytotoxicity on c-Met-addicted
cells as crizotinib which inhibits multi-kinases including c-
Met. That’s why we think our compound may be a superior
therapeutic agent to crizotinib for c-Met targeted therapy.
Figure 3 shows why c-Met inhibitors had effects only on c-
Met over-expressed cells not on c-Met low-expressed cells.
Downstream signals, such as Akt, and Erk, were diminished
by c-Met inhibitors only in c-Met over-expressed cells
(Figure 3, Additional file 1: Figure S2). In addition, total
Fig. 4 c-Met inhibitors induce G1/S arrest to suppress the proliferation of c-Met over-expressed cells. a-b SNU1 (a) or SNU5 (b) was treated with
DMSO or c-Met inhibitors for 24 h. Cells were collected to be analyzed for cell cycle distribution by NucleoCounter NC-250 instrument according
to the manufacture’s instruction. M1, M2, M3, and M4 indicate subG1, G1, S, G2/M phase respectively. c The populations of each phase are shown
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cellular tyrosine phosphorylations were diminished by
c-Met inhibitors only in c-Met over-expressed cells.
(Additional file 1: Figure S3) These phenomena can be
explained by ‘oncogene-addiction’. That is, c-Met over-
expressed gastric cancer cells are ‘addicted’ to c-Met
signaling. Therefore, c-Met-targeted therapeutics is quite
relevant to gastric cancer patients with c-Met overexpres-
sion. One thing interesting is that c-Met inhibitors induced
G1/S arrest in c-Met-addicted cells (Fig. 4) All of the suc-
cessful agents for cancer targeted therapy, such as imatinib,
sorafenib and gefitinib, have shown strong G1/S arrest to
result in apoptosis [39–41]. If we get to know the exact
mechanism how these agents cause G1/S arrest, it may
widen our perception of cancer therapy. To see the in vivo
efficacy of our compounds, we used mouse Hs746T
xenograft model. KRC-00715 shows the significant tumor
growth inhibition at doses of 50 mpk without loss of
weight. However, we suspended the in vivo experiment
with KRC-00509 because of the compound’s severe
toxicity to mouse.
Conclusions
In summary, we demonstrate newly synthesized c-Met
inhibitor which is orally available. KRC-00715 is highly
selective to c-Met, and shows excellent efficacy in vitro
and in vivo.
Additional file
Additional file 1: Figure S1. Inhibition Curve. The inhibition percentage
was measured in c-Met enzyme assay. The detailed assay procedures are
described in Methods. Figure S2. Phosphorylation of Akt and Erk is
downregulated by c-Met inhibitors only in c-Met overexpressed cells.
SNU-638 (A), SNU-620 (B), SNU-1 (C), or MKN-1 (D) cells were treated
with KRC-00509 or crizotinib in dose dependent manner for 3 hr. Cell
lysates were prepared for immunoblot with phospho antibodies of c-Met,
Akt, and Erk. Tubulin band shows equal loading. Figure S3. Total tyrosine
phosphorylations were reduced by c-Met inhibitors in c-Met overexpressed
cells. Hs746T (A), or AGS (B) were treated with c-Met inhibitors or crizotinib
in dose dependent manner for 3 hr. Cell lysates were prepared for
immunoblot with phospho tyrosine antibody. (PPTX 6747 kb)
Abbreviations
EGFR: Epidermal growth factor receptor; HGF: Hepatocyte growth factor;
HTRF: Homogeneous time resolved fluorescence; PEG: Polyethylene glycol;
PI3K: Phosphoinositide 3-kinase; RTK: Receptor tyrosine kinase;
SA-XL665: Streptavidine-XL665; VEGF: Vascular Endothelial Growth Factor.
Competing interests
The author’s declare that they have no competing interests.
Authors’ contributions
CHP, SUC have made substantial contributions to the conception, design of
research and writing the manuscript. SYC, JDH, HJ, CHC, and HRK made the
compounds. COL and HKL performed the in vivo xenograft assay. IYJ and
CHP contributed to the in vitro data including enzyme assay, cell cytotoxic
assay, cell cycle analysis and western blot. All authors read and approved the
final manuscript.
Acknowledgement
This study was supported by a grant of the Technology Innovation Program
(10038744) of Korea Evaluation Institute of Industrial Technology (KEIT)
funded by MOTIE, Republic of Korea.
Author details
1Bio-Organic Science Division, Korea Research Institute of Chemical
Technology, PO Box 107, Daejeon 305-600, Republic of Korea. 2Medicinal
Chemistry and Pharmacology, Korea University of Science and Technology,
Daejeon 305-350, Republic of Korea.
Received: 21 April 2015 Accepted: 10 January 2016
References
1. Weinstein IB. Cancer. Addiction to oncogenes–the Achilles heal of cancer.
Science. 2002;297(5578):63–4. doi:10.1126/science.1073096.
2. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature. 2001;411(6835):
355–65. doi:10.1038/35077225.
3. Giordano S, Ponzetto C, Di Renzo MF, Cooper CS, Comoglio PM. Tyrosine
kinase receptor indistinguishable from the c-met protein. Nature. 1989;
339(6220):155–6. doi:10.1038/339155a0.
4. Park M, Dean M, Kaul K, Braun MJ, Gonda MA, Vande WG. Sequence of MET
protooncogene cDNA has features characteristic of the tyrosine kinase family
of growth-factor receptors. Proc Natl Acad Sci U S A. 1987;84(18):6379–83.
Fig. 5 In vivo Hs746T xenograft assay. Hs746T cells were implanted
into the mouse and allowed to grow to the designated size. Vehicle
and KRC-00715 were orally administered to mouse daily at dose of
50 mpk. a Tumor sizes were measured using calipers throughout the
treatment period. *, P ≤ 0.001 , median tumor volumes are signifi-
cantly less in the treated versus the control group as determined
using one-way ANOVA. b Weights were measured throughout the
treatment period
Park et al. BMC Cancer  (2016) 16:35 Page 8 of 9
5. Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF, et
al. Identification of the hepatocyte growth factor receptor as the c-met
proto-oncogene product. Science. 1991;251(4995):802–4.
6. Zhang YW, Vande Woude GF. HGF/SF-met signaling in the control of
branching morphogenesis and invasion. J Cell Biochem. 2003;88(2):408–17.
doi:10.1002/jcb.10358.
7. Corso S, Comoglio PM, Giordano S. Cancer therapy: can the challenge be
MET? Trends Mol Med. 2005;11(6):284–92. doi:10.1016/j.molmed.2005.04.005.
8. Birchmeier C, Gherardi E. Developmental roles of HGF/SF and its receptor,
the c-Met tyrosine kinase. Trends Cell Biol. 1998;8(10):404–10.
9. Parikh RA, Wang P, Beumer JH, Chu E, Appleman LJ. The potential roles of
hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer
treatment. Onco Targets Ther. 2014;7:969–83. doi:10.2147/OTT.S40241.
10. Tsarfaty I, Rong S, Resau JH, Rulong S, da Silva PP, Vande Woude GF. The
Met proto-oncogene mesenchymal to epithelial cell conversion. Science.
1994;263(5143):98–101.
11. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met,
metastasis, motility and more. Nat Rev Mol Cell Biol. 2003;4(12):915–25.
doi:10.1038/nrm1261.
12. Lutterbach B, Zeng Q, Davis LJ, Hatch H, Hang G, Kohl NE, et al. Lung cancer cell
lines harboring MET gene amplification are dependent on Met for growth and
survival. Cancer Res. 2007;67(5):2081–8. doi:10.1158/0008-5472.CAN-06-3495.
13. Smolen GA, Sordella R, Muir B, Mohapatra G, Barmettler A, Archibald H, et al.
Amplification of MET may identify a subset of cancers with extreme
sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl
Acad Sci U S A. 2006;103(7):2316–21. doi:10.1073/pnas.0508776103.
14. Kuniyasu H, Yasui W, Kitadai Y, Yokozaki H, Ito H, Tahara E. Frequent
amplification of the c-met gene in scirrhous type stomach cancer. Biochem
Biophys Res Commun. 1992;189(1):227–32.
15. Tsujimoto H, Sugihara H, Hagiwara A, Hattori T. Amplification of growth
factor receptor genes and DNA ploidy pattern in the progression of gastric
cancer. Virchows Arch. 1997;431(6):383–9.
16. Hara T, Ooi A, Kobayashi M, Mai M, Yanagihara K, Nakanishi I. Amplification
of c-myc, K-sam, and c-met in gastric cancers: detection by fluorescence in
situ hybridization. Lab Invest. 1998;78(9):1143–53.
17. Miller CT, Lin L, Casper AM, Lim J, Thomas DG, Orringer MB, et al.
Genomic amplification of MET with boundaries within fragile site FRA7G
and upregulation of MET pathways in esophageal adenocarcinoma.
Oncogene. 2006;25(3):409–18. doi:10.1038/sj.onc.1209057.
18. Zhao X, Weir BA, LaFramboise T, Lin M, Beroukhim R, Garraway L, et al.
Homozygous deletions and chromosome amplifications in human lung
carcinomas revealed by single nucleotide polymorphism array analysis.
Cancer Res. 2005;65(13):5561–70. doi:10.1158/0008-5472.CAN-04-4603.
19. Marano L, Chiari R, Fabozzi A, De Vita F, Boccardi V, Roviello G, et al. c-Met
targeting in advanced gastric cancer: An open challenge. Cancer Lett.
2015;365(1):30–6. doi:10.1016/j.canlet.2015.05.028.
20. Cunningham D, Jost LM, Purkalne G, Oliveira J, Force EGT. ESMO Minimum
Clinical Recommendations for diagnosis, treatment and follow-up of gastric
cancer. Ann Oncol. 2005;16 Suppl 1:i22–3. doi:10.1093/annonc/mdi812.
21. Liu L, Wu N, Li J. Novel targeted agents for gastric cancer. J Hematol Oncol.
2012;5:31. doi:10.1186/1756-8722-5-31.
22. Munshi N, Jeay S, Li Y, Chen CR, France DS, Ashwell MA, et al. ARQ 197,
a novel and selective inhibitor of the human c-Met receptor tyrosine kinase
with antitumor activity. Mol Cancer Ther. 2010;9(6):1544–53. doi:10.1158/
1535-7163.MCT-09-1173.
23. Liu X, Wang Q, Yang G, Marando C, Koblish HK, Hall LM, et al.
A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling,
neoplastic activities, and cross-talk with EGFR and HER-3. Clin Cancer Res.
2011;17(22):7127–38. doi:10.1158/1078-0432.CCR-11-1157.
24. Christensen JG, Schreck R, Burrows J, Kuruganti P, Chan E, Le P, et al.
A selective small molecule inhibitor of c-Met kinase inhibits
c-Met-dependent phenotypes in vitro and exhibits cytoreductive
antitumor activity in vivo. Cancer Res. 2003;63(21):7345–55.
25. Abounader R, Lal B, Luddy C, Koe G, Davidson B, Rosen EM, et al.
In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes
inhibits glioma growth and angiogenesis and promotes apoptosis.
FASEB J. 2002;16(1):108–10. doi:10.1096/fj.01-0421fje.
26. Date K, Matsumoto K, Kuba K, Shimura H, Tanaka M, Nakamura T.
Inhibition of tumor growth and invasion by a four-kringle antagonist
(HGF/NK4) for hepatocyte growth factor. Oncogene. 1998;17(23):3045–54.
doi:10.1038/sj.onc.1202231.
27. Burgess T, Coxon A, Meyer S, Sun J, Rex K, Tsuruda T, et al. Fully human
monoclonal antibodies to hepatocyte growth factor with therapeutic
potential against hepatocyte growth factor/c-Met-dependent human
tumors. Cancer Res. 2006;66(3):1721–9. doi:10.1158/0008-5472.CAN-05-3329.
28. Sattler M, Pride YB, Ma P, Gramlich JL, Chu SC, Quinnan LA, et al. A novel
small molecule met inhibitor induces apoptosis in cells transformed by the
oncogenic TPR-MET tyrosine kinase. Cancer Res. 2003;63(17):5462–9.
29. Buchanan SG, Hendle J, Lee PS, Smith CR, Bounaud PY, Jessen KA, et al.
SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET
receptor tyrosine kinase with antitumor activity in vivo. Mol Cancer Ther.
2009;8(12):3181–90. doi:10.1158/1535-7163.MCT-09-0477.
30. Cui JJ, McTigue M, Nambu M, Tran-Dube M, Pairish M, Shen H, et al.
Discovery of a novel class of exquisitely selective mesenchymal-epithelial
transition factor (c-MET) protein kinase inhibitors and identification of the
clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-
b]pyrazin-6-yl)-1H-pyrazol-1 -yl)ethanol (PF-04217903) for the treatment of
cancer. J Med Chem. 2012;55(18):8091–109. doi:10.1021/jm300967g.
31. Gozdzik-Spychalska J, Szyszka-Barth K, Spychalski L, Ramlau K, Wojtowicz J,
Batura-Gabryel H, et al. C-MET inhibitors in the treatment of lung cancer.
Curr Treat Options Oncol. 2014;15(4):670–82. doi:10.1007/s11864-014-0313-5.
32. Asaoka Y, Tada M, Ikenoue T, Seto M, Imai M, Miyabayashi K, et al. Gastric
cancer cell line Hs746T harbors a splice site mutation of c-Met causing
juxtamembrane domain deletion. Biochem Biophys Res Commun.
2010;394(4):1042–6. doi:10.1016/j.bbrc.2010.03.120.
33. Nessling M, Solinas-Toldo S, Wilgenbus KK, Borchard F, Lichter P. Mapping
of chromosomal imbalances in gastric adenocarcinoma revealed amplified
protooncogenes MYCN, MET, WNT2, and ERBB2. Genes Chromosomes
Cancer. 1998;23(4):307–16.
34. Sakakura C, Mori T, Sakabe T, Ariyama Y, Shinomiya T, Date K, et al. Gains,
losses, and amplifications of genomic materials in primary gastric cancers
analyzed by comparative genomic hybridization. Genes Chromosomes
Cancer. 1999;24(4):299–305.
35. McDermott U, Sharma SV, Dowell L, Greninger P, Montagut C, Lamb J, et al.
Identification of genotype-correlated sensitivity to selective kinase inhibitors
by using high-throughput tumor cell line profiling. Proc Natl Acad Sci
U S A. 2007;104(50):19936–41. doi:10.1073/pnas.0707498104.
36. Yamazaki S, Skaptason J, Romero D, Lee JH, Zou HY, Christensen JG, et al.
Pharmacokinetic-pharmacodynamic modeling of biomarker response and
tumor growth inhibition to an orally available cMet kinase inhibitor in
human tumor xenograft mouse models. Drug Metab Dispos. 2008;36(7):
1267–74. doi:10.1124/dmd.107.019711.
37. Oser MG, Janne PA. A severe photosensitivity dermatitis caused by crizotinib.
J Thorac Oncol. 2014;9(7):e51–3. doi:10.1097/JTO.0000000000000163.
38. Ishii T, Iwasawa S, Kurimoto R, Maeda A, Takiguchi Y, Kaneda M. Crizotinib-
Induced Abnormal Signal Processing in the Retina. PLoS ONE. 2015;10(8):
e0135521. doi:10.1371/journal.pone.0135521.
39. Tracy S, Mukohara T, Hansen M, Meyerson M, Johnson BE, Janne PA.
Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line
H3255. Cancer Res. 2004;64(20):7241–4. doi:10.1158/0008-5472.CAN-04-1905.
40. Yin T, Wu YL, Sun HP, Sun GL, Du YZ, Wang KK, et al. Combined effects of
As4S4 and imatinib on chronic myeloid leukemia cells and BCR-ABL
oncoprotein. Blood. 2004;104(13):4219–25. doi:10.1182/blood-2004-04-1433.
41. Broecker-Preuss M, Muller S, Britten M, Worm K, Schmid KW, Mann K, et al.
Sorafenib inhibits intracellular signaling pathways and induces cell cycle
arrest and cell death in thyroid carcinoma cells irrespective of
histological origin or BRAF mutational status. BMC Cancer. 2015;15:184.
doi:10.1186/s12885-015-1186-0.
Park et al. BMC Cancer  (2016) 16:35 Page 9 of 9
